再鼎醫藥-SB(09688.HK)於香港聯交所自願轉換為雙重主要上市
格隆匯6月23日丨再鼎醫藥-SB(09688.HK)發佈公吿,有關董事會批准尋求於香港聯交所主板自願轉換為雙重主要上市的動議,及有關收到香港聯交所轉為主要上市申請收悉確認。 2022年6月27日,公司自願將其於香港聯交所的第二上市地位轉換為於香港聯交所的雙重主要上市將生效。於主要轉換生效日期,公司將成為於香港聯交所及納斯達克全球市場雙重主要上市的公司,且將自其股票簡稱中刪除股票標記“S”。
2022年6月,F. Ty Edmondson先生及歐陽麗妮女士獲委任為公司的聯席公司祕書,自2022年6月27日起生效。主要轉換後,William Ki Chul Cho先生將不再為公司香港上市規則第3.05條下的授權代表,自2022年6月27日起生效,及李偉斌律師行將不再為香港法例第622章公司條例第16部下的代表公司於香港接受送達法律程序文件及通知書的授權代表,自2022年6月27日起生效。Cho先生將仍為公司首席財務官。
歐陽女士根據香港上市規則第3.05條獲委任為公司授權代表;及根據香港法例第622章公司條例第16部獲委任為代表公司於香港接收法律程序文件及通知書的公司授權代表,自2022年6月27日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.